Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. - Wikidata - wikimedia - TriplyDB

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

http://www.wikidata.org/entity/Q42206973

about

Irradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivo Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines Biologics in dermatology.Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.Metastatic melanoma - a review of current and future drugs Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.Targeted therapy for melanoma: rational combinatorial approaches.Melanoma metastasis: new concepts and evolving paradigms.Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.Crosstalk signaling in targeted melanoma therapy.Modeling tandem AAG8-MEK inhibition in melanoma cells.A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Targeting invasive properties of melanoma cells.Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure Hyperalgesic priming (type II) induced by repeated opioid exposure: maintenance mechanisms.Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model.The inhibition of invasion of human melanoma cells through N-cadherin knock-down.BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1

P2860

Q28485143-E23834F6-5630-48B4-819E-7ED18271F154 Q28538149-9E01AE5A-91AB-45AB-9B6E-57D52A992E71 Q28544422-05E68D0C-73F2-4338-A99D-3F22D659780D Q34203684-C784621D-FE50-4DFC-9A0D-62A71D672C7E Q36140620-848AEE53-FAA1-44B1-8F7C-32B6A5CA082E Q36389868-41D2F622-4CA1-4D93-A027-D9F27DC3B3BF Q36557486-70058E9C-E022-4734-83AB-12CC00F7172F Q36757582-7E6607FE-D947-4FAE-962C-6AEFA4E0658B Q37161421-006A1A83-DD83-441C-A183-CE3745C385AF Q37277398-5074761A-1D77-40C0-BA0C-F3C1A41947E3 Q37410604-861F6FD1-65F7-4B2C-B6D5-1F0300717067 Q37450733-8F76CDC4-5588-4C13-B3E0-404BA29C385F Q37660341-F3CCBAA2-24AB-4E8E-80F6-452297ECB1BB Q38082327-CD4A0982-6936-4CA1-A772-8196B31F1110 Q38111220-F9D762AF-5770-4680-9841-2C7B362C4B46 Q38439387-1706D00C-8913-4B85-83D1-3C9831C61CC5 Q38619615-3EC13207-C3B3-432F-829B-6B3E633E5075 Q38757522-1196BF17-B5AA-499B-9F31-253B4D0408FD Q39014901-AF43DFE4-1648-4290-976C-975EEFA53050 Q39061829-0F201A56-BB48-42AB-B5C0-A5990765ECB2 Q39107981-5D663CFE-34E3-4D81-A004-61C21FDBA7E1 Q39135139-937B48E8-EF5B-4FF5-AB78-970683B9CC02 Q41198115-5BD68123-D3F9-4154-AFDA-DBF9A0FC7D0F Q44344074-9B6D6577-96E0-4FF0-8BEC-2514C832384D Q47121474-B121B2D2-A744-4618-AC3A-3C088ADF6B40 Q50005441-14F22D8D-3C43-41CC-BB28-2F354E8B04A4 Q52888231-195FC990-3234-4AA1-8AA4-D31C52AB27D7 Q54982629-F4D9FDA7-34B8-4D15-A48D-A3EF0E1B143A Q58712577-CFE7104E-C36D-4FD1-B7FC-5F6C44476B67

P2860

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

http://www.wikidata.org/entity/Q42206973

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@en

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@nl

type

label

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@en

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@nl

prefLabel

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@en

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@nl

P1433

Q42206973-1F16D32E-6A18-4D1E-965E-C2E23872BA43

P1476

Q42206973-DF7905AD-44DF-47A4-BE17-9FDEBB05B53F

P2093

Q42206973-122E7A29-6561-43DD-AE06-D7E230A19A63

Q42206973-3546995D-9C39-4C63-B5CE-1FEDFE99E8CD

Q42206973-C69B629E-6AA2-4AD5-88F5-D20CBCF79ECA

Q42206973-EE89D3B3-1CD1-4A9B-A5EC-D1DCF1E1B1BD

P2860

Q42206973-0B37F7CF-54BB-4294-A24D-8FCB4A7FF3E7

Q42206973-119570CE-FCF1-45AC-8259-F79C1063F7A5

Q42206973-185E9213-DBC1-435C-B41C-8433444338B5

Q42206973-1E1B8679-96E8-4D01-9920-D92E0A28B567

Q42206973-217C2BD9-1FE3-4C4F-A748-C84338477607

Q42206973-21E25C5B-CD63-4E3E-8CB3-8B4860F57D8F

Q42206973-2B789A14-1B5B-40F0-A0D9-79DE8A13A11E

Q42206973-2D3610FE-86CC-4721-8444-574ABA38639C

Q42206973-2EA521D7-C0C5-4928-8889-52FFA2C78B9C

Q42206973-340C3798-BC89-4309-BF99-2541331B7432

P2888

Q42206973-1B57AF50-B04C-477E-858D-BA46AFF8FD61

P304

Q42206973-7B7AFFCB-0C82-4530-9B2E-161417C9E069

P31

Q42206973-A0C7A44C-7889-4C18-A0BB-CDBBBAE937BD

P356

Q42206973-CDD66FC3-60E1-4AB1-8207-B99ED5ED2F94

P407

Q42206973-3F3A2BB0-5247-41EE-9455-6BF1D485635F

P433

Q42206973-06A203B3-D513-41A8-8AA9-FE2980432B1E

P478

Q42206973-9349A74D-B279-41A8-BB57-A2D525E36A7E

P577

Q42206973-C436C90A-920D-4CC1-BD5B-7AE77253FE43

P5875

Q42206973-FDFA637F-21D1-43EF-888D-8F9E63352AF1

P6179

Q42206973-B245EFB3-5CC9-48B4-B934-08B337DE3829

P698

Q42206973-D3ADC178-4CCE-4732-8965-7F9CF6EF1D33

P932

Q42206973-B4362A04-07F3-456A-86D1-40BA40FDE643

P356

P1433

P1476

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

@en

P2093

C Wellbrock

http://www.w3.org/2001/XMLSchema#string

I Arozarena

http://www.w3.org/2001/XMLSchema#string

J Ferguson

http://www.w3.org/2001/XMLSchema#string

M Ehrhardt

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Cell motility through plasma membrane blebbing

Regulation of cell motility by mitogen-activated protein kinase

Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion.

Rac activation and inactivation control plasticity of tumor cell movement

Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis

Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis

Extracellular signal-regulated kinase promotes Rho-dependent focal adhesion formation by suppressing p190A RhoGAP.

P2888

P304

86-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2012.25

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221810707

http://www.w3.org/2001/XMLSchema#string

P6179

1036610219

http://www.w3.org/2001/XMLSchema#string

P698

22310287

http://www.w3.org/2001/XMLSchema#string

P932

3378628

http://www.w3.org/2001/XMLSchema#string